Crispr therapeutics ag (CRSP)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Sep'15
Collaboration revenue

157

77,016

211,928

318

328

115

563

1,088

1,358

32,325

2,387

3,582

2,703

2,344

1,549

795

476

-

Operating expenses:
Research and development

54,193

48,761

57,246

39,533

33,822

28,801

39,820

25,633

19,519

20,030

17,845

17,120

14,805

15,572

12,052

8,602

6,012

3,749

General and administrative

19,550

17,272

15,519

15,768

14,929

16,542

10,175

12,741

8,836

11,323

8,112

7,768

8,642

12,082

4,107

8,751

6,116

2,453

Total operating expenses

73,743

66,033

72,765

55,301

48,751

45,343

49,995

38,374

28,355

31,353

25,957

24,888

23,447

27,654

16,159

17,353

12,128

6,202

Loss from operations

-73,586

10,983

139,163

-54,983

-48,423

-45,228

-49,432

-37,286

-26,997

972

-23,570

-21,306

-20,744

-25,310

-14,610

-16,558

-11,652

-6,202

Other income (expense):
Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

1

-1

0

-8,050

-8

Loss from equity method investment

-

0

-3,430

-1,012

-1,025

-1,019

-1,012

-1,153

-1,091

-453

-359

-505

-446

-

-

-686

-

-

Other income, net

4,232

-

-

-

1,125

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on extinguishment of convertible loan

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

11,482

-

Other income (expense), net

-

-

2,964

2,381

-

-1,109

-130

155

-126

41

-71

-161

-6

78,653

-75

80

-146

9

Total other income, net

4,232

19,563

-466

1,369

100

-2,128

-1,142

-998

-1,217

-412

-430

-666

-452

42,808

-76

-606

3,286

1

Net loss before income taxes

-69,354

30,546

138,697

-53,614

-48,323

-47,356

-50,574

-38,284

-28,214

560

-24,000

-21,972

-21,196

17,498

-14,686

-17,164

-8,366

-6,201

Provision for income taxes

400

-52

300

100

100

267

100

100

86

420

707

343

279

400

8

0

76

153

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-21,475

17,098

-14,694

-17,164

-8,442

-6,354

Net loss

-69,731

30,542

138,423

-53,699

-48,408

-47,590

-50,711

-38,380

-28,300

-

-24,707

-22,315

-

17,099

-14,680

-17,157

-8,439

-6,353

Loss attributable to noncontrolling interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-1

-14

-7

-3

-1

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-21,475

17,098

-14,694

-17,164

-8,442

-6,354

Foreign currency translation adjustment

-25

29

-12

-10

8

-7

-6

-21

12

2

8

6

24

0

-1

-13

-4

-4

Comprehensive loss

-69,756

30,571

138,411

-53,709

-48,400

-47,597

-50,717

-38,401

-28,288

142

-24,699

-22,309

-21,451

17,098

-14,695

-17,177

-8,446

-6,358

Reconciliation of net income (loss) to net income (loss) attributable to common shareholders:
Net income (loss) per share attributable to common shareholders— basic

-

0.53

2.52

-

-

-

-1.07

-

-

-

-

-

-

-

-

-

-

-

Weighted-average common shares outstanding used in net income (loss) per share attributable to common shareholders—basic

-

57,395

54,829

-

-

-

47,391

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) per share attributable to common shareholders— diluted

-

0.51

2.40

-

-

-

-1.07

-

-

-

-

-

-

-

-

-

-

-

Weighted-average common shares outstanding used in net income (loss) per share attributable to common shareholders—diluted

-

60,233

57,598

-

-

-

47,391

-

-

-

-

-

-

-

-

-

-

-

Net loss per share attributable to common shareholders—basic and diluted

-1.15

-

-

-1.01

-0.93

-

-

-0.82

-0.62

-

-0.62

-0.56

-0.54

5.56

-2.77

-3.15

-1.53

-1.15

Weighted-average common shares outstanding used in net loss per share attributable to common shareholders—basic and diluted

60,847

-

-

53,188

52,093

-

-

46,842

45,877

-

40,088

39,895

39,725

32,760

5,292

5,448

5,528

5,528